AI-Powered Weapons Startup Raises $1.5B & Mou...

#921: The economic world prepares for Jackson Hole and all eyes are on Kevin Warsh to deliver a clearer message on the state of inflation in the US. Shein, once valued at $100B, is now aiming for a $27B valuation as it makes its stock market debut. A new drug can lengthen the lif ...  Show more

#920: Meta settles a major case that alleges its platforms can be addictively harmful for teens. Nvidia has become a banker to the AI boom. Bill Gates expresses his concerns about the pace of AI and society’s ability to govern it in an essay. NYC passes SF as the country’s bigges ...  Show more

 Bloomberg News Health Reporter Madison Muller explains how Pfizer’s second weight-loss setback this year is a warning sign that breaking into the lucrative obesity market isn’t going to be easy. Cory Klippsten, CEO at Swan Bitcoin, shares his crypto outlook for 2024. Benjamin Wo ...  Show more

Bloomberg Opinion Pharma Columnist Lisa Jarvis and Bloomberg News Health Reporter Madison Muller discuss a how a clinical trial in obesity drugs is punctuating a string of positive developments that could make the treatments more widely accessible. Kate Hao, Founder and CEO of Ha ...  Show more

Kara and Scott discuss declining social media traffic to news sites, Amazon using an algorithm to test how high they could boost prices, and why the boom in weight loss drugs is the “biggest business story of the year.” Also, Kevin McCarthy’s historic ouster marks another predict ...  Show more

Palantir lifted its 2025 revenue guidance and Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera. Plus, OpenAI inked a $38bn computing deal with Amazon, and the FT’s Claire Jones explains how the Trump administration is considering pushing fo ...  Show more